Alkem Laboratories Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-07-17
Stock price
₹5563.00
Market cap
66,516 Cr
Stock P/E
28.3
P/B
4.64
Dividend yield
0.9%
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,968 Cr | 3,440 Cr | 3,324 Cr | 2,936 Cr | 3,032 Cr | 3,415 Cr | 3,374 Cr | 3,144 Cr | 3,371 Cr | 4,001 Cr | 3,737 Cr | 3,603 Cr |
| Operating expenses (approx.) | 2,579 Cr | 2,751 Cr | 2,668 Cr | 2,458 Cr | 2,423 Cr | 2,662 Cr | 2,615 Cr | 2,607 Cr | 2,619 Cr | 3,080 Cr | 2,962 Cr | 3,021 Cr |
| EBITDA | 389 Cr | 689 Cr | 656 Cr | 478 Cr | 609 Cr | 753 Cr | 759 Cr | 537 Cr | 752 Cr | 921 Cr | 775 Cr | 582 Cr |
| OPM % | 13.1% | 20.0% | 19.7% | 16.3% | 20.1% | 22.0% | 22.5% | 17.1% | 22.3% | 23.0% | 20.7% | 16.2% |
| Other income | 66 Cr | 63 Cr | 94 Cr | 88 Cr | 120 Cr | 134 Cr | 93 Cr | 146 Cr | 136 Cr | 104 Cr | 143 Cr | 200 Cr |
| Interest | 30 Cr | 30 Cr | 25 Cr | 27 Cr | 29 Cr | 28 Cr | 36 Cr | 28 Cr | 30 Cr | 35 Cr | 42 Cr | 54 Cr |
| Depreciation | 72 Cr | 74 Cr | 70 Cr | 83 Cr | 80 Cr | 79 Cr | 85 Cr | 112 Cr | 88 Cr | 94 Cr | 95 Cr | 106 Cr |
| Profit before tax | 353 Cr | 648 Cr | 655 Cr | 367 Cr | 619 Cr | 780 Cr | 731 Cr | 396 Cr | 771 Cr | 896 Cr | 781 Cr | 423 Cr |
| Tax % | 18.4% | 5.1% | 7.7% | 17.1% | 11.2% | 10.0% | 12.3% | 18.5% | 13.3% | 13.0% | 16.3% | 40.5% |
| Net profit | 288 Cr | 615 Cr | 604 Cr | 304 Cr | 550 Cr | 702 Cr | 641 Cr | 322 Cr | 668 Cr | 779 Cr | 653 Cr | 251 Cr |
| EPS (₹) | ₹23.98 | ₹51.90 | ₹49.76 | ₹24.55 | ₹45.60 | ₹57.60 | ₹52.34 | ₹25.57 | ₹55.56 | ₹63.99 | ₹53.19 | ₹19.77 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2019Standalone only | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 7,357 Cr | 8,344 Cr | 8,865 Cr | 10,634 Cr | 11,599 Cr | 12,668 Cr | 12,965 Cr | 14,712 Cr | Sign in for TTM |
| Operating expenses (approx.) | 6,155 Cr | 6,767 Cr | 6,923 Cr | 8,434 Cr | 10,093 Cr | 10,544 Cr | 9,959 Cr | 11,299 Cr | Sign in for TTM |
| EBITDA | 1,202 Cr | 1,578 Cr | 1,942 Cr | 2,201 Cr | 1,506 Cr | 2,124 Cr | 3,006 Cr | 3,414 Cr | Sign in for TTM |
| OPM % | 16.3% | 18.9% | 21.9% | 20.7% | 13.0% | 16.8% | 23.2% | 23.2% | Sign in for TTM |
| Other income | 88 Cr | 104 Cr | 233 Cr | 163 Cr | 216 Cr | 311 Cr | 494 Cr | 583 Cr | Sign in for TTM |
| Interest | 55 Cr | 65 Cr | 59 Cr | 52 Cr | 107 Cr | 112 Cr | 122 Cr | 161 Cr | Sign in for TTM |
| Depreciation | 193 Cr | 253 Cr | 275 Cr | 304 Cr | 310 Cr | 299 Cr | 357 Cr | 382 Cr | Sign in for TTM |
| Profit before tax | 955 Cr | 1,260 Cr | 1,842 Cr | 1,844 Cr | 1,305 Cr | 2,023 Cr | 2,527 Cr | 2,871 Cr | Sign in for TTM |
| Tax % | 19.0% | 8.8% | 12.2% | 8.9% | 22.8% | 10.5% | 12.3% | 18.0% | Sign in for TTM |
| Net profit | 774 Cr | 1,149 Cr | 1,618 Cr | 1,680 Cr | 1,007 Cr | 1,811 Cr | 2,215 Cr | 2,351 Cr | Sign in for TTM |
| EPS (₹) | ₹63.61 | ₹94.26 | ₹132.57 | ₹137.63 | ₹82.31 | ₹150.19 | ₹181.11 | ₹192.51 | Sign in for TTM |
| Dividend payout % | — | — | — | 25.1% | 52.6% | 29.8% | 22.8% | 26.1% | Sign in for TTM |
Sign in for TTM
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2019Standalone only | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 24 Cr | 24 Cr | 24 Cr | 24 Cr | 24 Cr | 24 Cr | 24 Cr | 24 Cr |
| Reserves | 5,415 Cr | 0.0000 Cr | 7,353 Cr | 8,614 Cr | 9,021 Cr | 10,288 Cr | 11,961 Cr | 14,325 Cr |
| Borrowings | 503 Cr | — | 1,670 Cr | — | 1,397 Cr | 1,214 Cr | 752 Cr | 1,131 Cr |
| Other liabilities | 1,324 Cr | — | 2,291 Cr | — | 2,925 Cr | 3,647 Cr | 4,506 Cr | 5,393 Cr |
| Total liabilities | 7,292 Cr | — | 11,519 Cr | — | 13,757 Cr | 15,575 Cr | 17,691 Cr | 20,873 Cr |
| Fixed assets (net) | 1,574 Cr | — | 2,234 Cr | — | 2,065 Cr | 2,161 Cr | 2,064 Cr | 2,695 Cr |
| CWIP | 382 Cr | — | 393 Cr | — | 310 Cr | 148 Cr | 477 Cr | 138 Cr |
| Investments | 1,696 Cr | — | 333 Cr | — | 622 Cr | 484 Cr | 1,846 Cr | 1,869 Cr |
| Other assets | 3,089 Cr | — | 6,954 Cr | — | 8,613 Cr | 10,421 Cr | 10,820 Cr | 12,217 Cr |
| Total assets | 7,292 Cr | — | 11,519 Cr | — | 13,757 Cr | 15,575 Cr | 17,691 Cr | 20,873 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2019Standalone only | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | — | 1,111 Cr | 1,683 Cr | 1,948 Cr | 1,913 Cr | 1,963 Cr |
| Cash from investing | — | — | — | -1,435 Cr | 113 Cr | -1,009 Cr | -1,299 Cr | -1,667 Cr |
| Cash from financing | — | — | — | 380 Cr | -1,761 Cr | -1,145 Cr | -811 Cr | -503 Cr |
| Net cash flow | — | — | — | 58 Cr | 42 Cr | -207 Cr | -186 Cr | -222 Cr |
| Free cash flow (OCF − Capex) | — | — | — | 772 Cr | 1,450 Cr | 1,689 Cr | 1,237 Cr | 1,346 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2019Standalone only | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | 18.6% | 5541.0% | 18.1% | 22.0% | 11.0% | 15.3% | 20.1% | 19.6% |
| ROE % | 14.0% | 0.0% | 21.0% | 19.1% | 10.4% | 16.8% | 17.4% | 16.0% |
| Debtor days | 62 | — | 66 | — | 67 | 65 | — | — |
| Inventory days | 241 | — | 352 | — | 310 | 295 | 309 | 340 |
| Days payable | 183 | — | 163 | — | 139 | 194 | — | — |
| Cash conversion cycle | 119 | — | 255 | — | 239 | 166 | 309 | 340 |
| Debt / equity | 0.09 | — | 0.23 | — | 0.15 | 0.12 | 0.06 | 0.08 |
| Current ratio | 1.86 | — | 1.92 | — | 2.32 | 2.61 | 2.73 | 2.55 |
| Net debt / EBITDA | 0.00 | 0.00 | 0.77 | 0.00 | 0.75 | 0.36 | 0.15 | 0.26 |
Compare with peers
Loading peers…